News Search Results
May 12, 2025, 03:59 ET Citrus Aurantium Extract Market to Reach $4,339.2 Million by 2027 in short term and $5,671.7 million by 2034 Globally, at 3.8% CAGR: Allied Market Research
aurantium extract industry include Activ'Inside, Foodchem International Corporation, Herbal Creations, Innophos, NaturMed Scientific, Nutra Green Biotechnology Co., Ltd., Nutraceuticals Group Europe Ltd., Shaanxi Jiahe Phytochem Co., Ltd. (Jiaherb), Sinerga S.p.A., and Xi'an Sost Biotech Co., Ltd. Key
More news about: Allied Market Research
May 12, 2025, 03:30 ET Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
May 12, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or "The Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary lateral CAR platform,
More news about: Leucid Bio
May 12, 2025, 01:41 ET CJ Foods Names Dr. Gregory Yep as its New Chief Executive Officer
Gregory Yep as its new chief executive officer. Yep has more than three decades of diverse leadership in food science, nutrition, and biotechnology across numerous consumer goods and food-related multinational businesses. Dr. Yep assumes leadership at a transformative moment for CJ Foods as
More news about: CJ Foods
May 11, 2025, 18:01 ET Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 09, 2025, 20:38 ET Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
Deep Track's investor presentation demonstrates that Deep Track fundamentally does not understand how to run a successful commercial stage biotechnology company. Deep Track's one-dimensional plan to strip-mine Dynavax ignores market realities and the clear need to have a diversified portfolio and
More news about: Dynavax Technologies